Catalyst Pharmaceuticals, Inc. (CPRX)
| Market Cap | 707.13M |
| Revenue (ttm) | 153.72M |
| Net Income (ttm) | 45.06M |
| Shares Out | 102.78M |
| EPS (ttm) | 0.42 |
| PE Ratio | 16.38 |
| Forward PE | 10.54 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 998,317 |
| Open | 6.84 |
| Previous Close | 6.87 |
| Day's Range | 6.62 - 6.94 |
| 52-Week Range | 4.81 - 8.65 |
| Beta | 1.29 |
| Analysts | Buy |
| Price Target | 11.17 (+62.4%) |
| Earnings Date | May 10, 2022 |
About CPRX
Catalyst Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies for people with rare debilitating, chronic neuromuscular, and neurological diseases in the United States. It offers Firdapse, an amifampridine phosphate tablets for the treatment of patients with lambert-eaton myasthenic syndrome (LEMS); and Ruzurgi for the treatment of pediatric LEMS patients. The company also develops Firdapse for the treatment of MuSK antibody positive myasthenia gravis, and spinal muscular atroph...
Financial Performance
In 2021, CPRX's revenue was $140.83 million, an increase of 18.27% compared to the previous year's $119.07 million. Earnings were $39.48 million, a decrease of -47.35%.
Financial StatementsAnalyst Forecast
According to 11 analysts, the average rating for CPRX stock is "Buy." The 12-month stock price forecast is 11.17, which is an increase of 62.35% from the latest price.
News
Catalyst Pharmaceuticals to Participate in Two Upcoming Investor Conferences
CORAL GABLES, Fla., May 17, 2022 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. ("Catalyst") (Nasdaq: CPRX), a commercial-stage biopharmaceutical company focused on in-licensing, developing, and com...
Catalyst Pharmaceuticals (CPRX) Q1 Earnings Miss, Revenues Up Y/Y
Catalyst's (CPRX) first-quarter 2022 earnings miss estimates while revenues meet the same.
Catalyst Pharmaceutical (CPRX) Misses Q1 Earnings and Revenue Estimates
Catalyst (CPRX) delivered earnings and revenue surprises of -14.29% and 0.19%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
Catalyst Pharmaceuticals Reports Record First Quarter 2022 Financial Results And Provides Corporate Update
Achieved Record Revenues of more than $43 Million, a 42.7% Increase YoY
Drug/Biotech Stocks' Q1 Earnings on May 10: EXEL, BHC & More
Let's look at the five biotech/drug companies that are slated to release quarterly results on May 10.
Catalyst Pharmaceuticals to Report First Quarter 2022 Financial Results on May 10, 2022
The Company to Host a Conference Call and Webcast on May 11, 2022, at 8:30 AM ET The Company to Host a Conference Call and Webcast on May 11, 2022, at 8:30 AM ET
Catalyst Pharmaceutical (CPRX) is a Top-Ranked Momentum Stock: Should You Buy?
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Catalyst (CPRX) Q4 Earnings Lag Estimates, Revenues Rise Y/Y
Catalyst's (CPRX) fourth-quarter 2021 earnings miss estimates while revenues slightly beat the mark.
Catalyst Pharmaceutical (CPRX) Q4 Earnings Lag Estimates
Catalyst (CPRX) delivered earnings and revenue surprises of -25% and 0.37%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?
Catalyst Pharmaceuticals Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Business Update
Total 2021 Revenues Increased Approximately 18% YoY to $141 Million
Catalyst Pharmaceuticals and KYE Pharmaceuticals Announce a Second Favorable Canadian Federal Court Ruling Setting As...
CORAL GABLES, Fla., March 11, 2022 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. ("Catalyst") (Nasdaq: CPRX), a commercial-stage, patient-centric biopharmaceutical company focused on in-licensing, ...
Catalyst (CPRX) Skyrockets 110% Over a Year: Here's Why
Catalyst's (CPRX) stock price has more than doubled in the past year, driven by its sole marketed drug, Firdapse, approved for the treatment of Lambert-Eaton Myasthenic Syndrome in adults.
Catalyst Pharmaceutical (CPRX) Earnings Expected to Grow: What to Know Ahead of Next Week's Release
Catalyst (CPRX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Catalyst Pharmaceuticals Named Among Forbes 2022 America's Best Small Companies
The Company Ranked 65th of More Than 1,000 Companies Assessed The Company Ranked 65th of More Than 1,000 Companies Assessed
Catalyst Pharmaceuticals to Report Fourth Quarter and Full-Year 2021 Financial Results on March 16, 2022
The Company Will Host a Conference Call and Webcast on March 17, 2022, at 8:30 AM ET The Company Will Host a Conference Call and Webcast on March 17, 2022, at 8:30 AM ET
4 Small Drug Stocks That Appear to Be Solid Bets in a Challenging Industry
Some business disruption due to COVID-19 was felt by the Medical-Drugs industry players in 2021. CPRX, KDNY, ASRT and SGTX may prove to be good additions to one's portfolio.
Catalyst Pharmaceuticals Further Strengthens FIRDAPSE® U.S. Patent Portfolio
Three New Patents Covering Additional Patient Amifampridine Metabolizer Types have been Allowed and will Issue in March 2022
Wall Street Analysts Predict a 25% Upside in Catalyst (CPRX): Here's What You Should Know
The average of price targets set by Wall Street analysts indicates a potential upside of 25.2% in Catalyst (CPRX). While the effectiveness of this highly sought-after metric is questionable, the positiv...
What Makes Catalyst (CPRX) a Good Fit for "Trend Investing"
Catalyst (CPRX) made it through our "Recent Price Strength" screen and could be a great choice for investors looking to make a profit from stocks that are currently on the move.
Catalyst Pharmaceuticals Teams Up with Patients and Advocacy Groups to Ring Nasdaq Opening Bell on Rare Disease Day 2022
Ceremony Recognizes Importance of Biopharma Industry and Advocacy Group Collaboration to Address Needs for New Treatments in Orphan and Rare Disorders
Catalyst Pharmaceuticals to Launch LEMS Aware Podcast on Rare Disease Day 2022
Initiative Part of Expansion of Education and Awareness Activities for Lambert-Eaton Myasthenic Syndrome Community Initiative Part of Expansion of Education and Awareness Activities for Lambert-Eaton My...
Here's Why Momentum in Catalyst (CPRX) Should Keep going
Catalyst (CPRX) made it through our "Recent Price Strength" screen and could be a great choice for investors looking to make a profit from stocks that are currently on the move.
Wall Street Analysts See a 33% Upside in Catalyst (CPRX): Can the Stock Really Move This High?
The consensus price target hints at a 33.3% upside potential for Catalyst (CPRX). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate r...
Catalyst's (CPRX) Stock Up on 2022 Guidance for Firdapse
Catalyst Pharmaceuticals (CPRX) reports preliminary sales figures for the fourth quarter. The company also provides its revenue guidance for 2022.